Dr Reddy’s submits Abatacept Biosimilar BLA to USFDA for review EP News Bureau Feb 23, 2026 351(k) Biologics License Application for DRL_AB IV infusion targets rheumatoid arthritis, psoriatic arthritis and pJIA
